Lincoln Pharmaceuticals Limited has received credit rating reaffirmation from CRISIL Limited, with the rating agency maintaining its assessment of the pharmaceutical company's financial strength and market position. The company announced on January 10, 2026, that it received the credit rating confirmation on January 09, 2026, under Regulation 30 of SEBI (LODR) Regulations, 2015.

Credit Rating Details

CRISIL has reaffirmed Lincoln Pharmaceuticals' credit ratings across its bank facilities totaling ₹102.00 crore. The rating structure demonstrates the company's strong creditworthiness across different facility types.

Financial Performance Highlights

The rating reaffirmation reflects Lincoln Pharmaceuticals' robust financial performance and market positioning. CRISIL's analysis incorporated the consolidated business and financial risk profiles of Lincoln Pharmaceuticals Limited and Zullinc Healthcare Ltd, referred to collectively as the Lincoln group.

Key Rating Strengths

CRISIL highlighted several factors supporting the rating reaffirmation. The company benefits from established market position with 1,700 registered products across more than 15 therapeutic segments. Lincoln Pharmaceuticals derives 60-65% of its revenue through exports, demonstrating strong international presence. The promoters bring more than three decades of experience in the pharmaceutical industry, contributing to revenue growth at a compound annual growth rate of 10.00% over five fiscals through 2024.

The financial risk profile remains healthy with consolidated networth of ₹671.00 crore against nil debt as of March 31, 2025. The company maintains strong liquidity with cash accruals expected to exceed ₹90.00 crore and current ratio of 4.33 times. Liquid investments stood at ₹173.10 crore in shares, debentures and mutual funds as of March 31, 2025.

Areas of Concern

CRISIL identified working capital-intensive operations as a key weakness, with gross current assets expected at 170-185 days over the medium term. The company has extended loans and advances of ₹141.00 crore as of March 31, 2025, compared to ₹104.00 crore in the previous year. The pharmaceutical sector's exposure to regulatory risks and intense competition remains a monitoring factor.

Bank Facility Breakdown

The rated facilities are distributed across multiple banking partners, providing diversified funding sources for the company's operations.

Outlook and Rating Sensitivity

CRISIL maintains a stable outlook for Lincoln Pharmaceuticals, expecting the company to continue benefiting from its established market presence and healthy financial risk profile. The rating agency indicated that upward factors could include revenue growth at 20.00% CAGR with steady operating margins and improved geographical diversification. Conversely, operating profitability below 13.00% or significant working capital stretch could pressure the ratings.

Lincoln Pharmaceuticals , a leading Indian healthcare company, has reported robust financial results for the first quarter, showcasing significant growth and outlining ambitious future plans.

Q1 Financial Highlights

Lincoln Pharma's Q1 results demonstrate strong performance across key financial metrics:

*All figures in ₹ crore

The company reported a standalone net profit of ₹27.70 crore for Q1, marking a 17% increase from ₹23.69 crore in the same period last year. Total income rose by 7.3% year-over-year to ₹169.34 crore. Notably, EBITDA showed impressive growth, reaching ₹39.08 crore, up 17.92% from ₹33.14 crore in Q1 of the previous year.

Strategic Growth and Expansion

Lincoln Pharmaceuticals has set ambitious targets for the coming years:

1. Revenue Goal: The company aims to achieve ₹1,000 crore in revenue within the next three years.
2. Annual Growth Rate: Lincoln Pharma is targeting a 15-18% annual growth rate.
3. Key Growth Segments: The company's growth strategy focuses on strong performance in cardiac, diabetic, dermatology, and ENT segments.
4. Business Expansion: The company plans to expand into high-value product lines and new markets.

Recent Developments

• Bulk Drug Manufacturing: During the quarter, the company launched its bulk drug manufacturing plant with a ₹4 crore investment from internal funds.
• Product Approvals: The company received approvals for 10 products.
• Stock Performance: Company shares surged 8.47% to close at ₹576.90 on BSE.

Company Profile

Lincoln Pharmaceuticals, established in 1979, has developed over 600 formulations across various therapeutic areas. The company's product portfolio includes treatments for anti-infective, respiratory, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, and anti-malarial conditions.

As Lincoln Pharmaceuticals continues to expand its product range and global presence, the company remains focused on providing affordable and innovative medicines for healthier lives, aligning with its vision of "Healthcare for All."